AgeX Therapeutics is focused on the development and commercialization of novel therapeutics targeting human aging. We are building upon the foundation of our proprietary technologies such as PureStemÂ® and induced Tissue Regeneration (iTRâ„¢) to develop innovative medicines designed to address some of the largest unsolved problems in aging. Through PureStemÂ® we have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging with a high unmet medical need. iTRâ„¢ is our revolutionary longevity platform aiming to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body. AGEX-BAT1 is AgeX Therapeutic’s preclinical cell therapy product candidate of brown adipocytes for the treatment of certain age-related metabolic disorders such as Type II diabetes. Dr. Michael West is the founder and CEO.